92.99 0.00 (0.00%)
After hours: 4:50PM EDT
|Bid||92.93 x 3100|
|Ask||92.94 x 1300|
|Day's Range||92.89 - 93.69|
|52 Week Range||72.30 - 93.69|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||17.28|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||104.00|
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...
Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.
Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale. Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed". Francesco Balestrieri, head of Sandoz's Europe region, will become interim CEO to oversee what Narasimhan called "a multi-year transformation program" in which Sandoz re-focuses on biosimilars -- copies of patent-expired biological drugs made by rivals -- and hard-to-make generics like insulin.
The head of Novartis’s generic drugs business, Sandoz, has stepped down, sparking fresh speculation about its future. Vas Narasimhan, chief executive of the Swiss drugmaker, said that Richard Francis, who has run Sandoz for the past five years, had “decided that for personal reasons he cannot commit to stay with Sandoz” for the duration of “a multiyear transformation programme”. Mr Francis’ departure will revive speculation that Mr Narasimhan, who has sought to focus the company on its higher margin innovative medicines business since taking charge last year, is eyeing a potential spin-off of Sandoz.
The chief compliance officer, once responsible for simply making sure companies stayed within legal bounds, is now responsible for a broader range of priorities. Among them: guarding a company’s reputation, ensuring investors and government agencies have the information they need, and strengthening internal culture around compliance efforts, executives said Tuesday during a panel discussion hosted by Dow Jones Risk & Compliance and The Wall Street Journal.
Celgene and Novartis could go head-to-head in a patent battle over multiple sclerosis treatment ozanimod, an analyst said Tuesday. Novartis has a key patent for the S1P modulator drug class.
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.
How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Business transformation Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company. According to the company’s
In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate, an intravenous treatment for certain types of cancer. Drug firm Novartis, which in 2018 acquired rights to sell it in Europe, is asking more than five times that for its proprietary version, Lutathera. Thomasa is part of a protest against high drug prices launched by an unlikely group of rebels: Dutch pharmacies.
How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Tax rate projectionsIn fiscal 2018, Novartis (NVS) and Bristol-Myers Squibb (BMY) reported an effective tax rate of 17.05% and 9.28%, respectively. In its fourth-quarter
How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Dividend guidance In fiscal 2018, Novartis (NVS) and Bristol-Myers Squibb (BMY) reported an annual dividend per share of $2.85 and $1.60, respectively. According to
Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.
How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Expenses guidance for fiscal 2019 In its fourth-quarter earnings investor presentation, Novartis (NVS) has guided for core net financial expenses for its new structure, which